CareDx in ‘early innings’ of sales growth acceleration, says Piper Jaffray. After traveling with management, Piper Jaffray analyst William Quirk continues to believe CareDx is in the “early innings” of a multiyear revenue acceleration story “that has several legs.” Management was upbeat about the pace of the AlloSure launch, with K-OAR center enrollment ahead of schedule, Quirk tells investors in a research note. The analyst encourages small cap growth funds to add to or establish positions in the stock and reiterates an Overweight rating on CareDx with a $14 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.